Scarica l'app Stockscreener
5.89
7.55%
-0.47
Precedente Chiudi:
$6.36
Aprire:
$6.21
Volume 24 ore:
99,420
Relative Volume:
0.99
Capitalizzazione di mercato:
$150.45M
Reddito:
-
Utile/perdita netta:
$-22.38M
Rapporto P/E:
-4.1773
EPS:
-1.41
Flusso di cassa netto:
$-15.54M
1 W Prestazione:
-8.55%
1M Prestazione:
-2.08%
6M Prestazione:
-36.43%
1 anno Prestazione:
-6.81%
Intervallo 1D:
$5.83
$6.21
Intervallo di 1 settimana:
$5.83
$7.00
Portata 52W:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Confronta NVCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
5.91 | 161.91M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.39 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.99 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.60 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.96 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.66 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Maxim Group | Buy |
| 2025-03-17 | Iniziato | Laidlaw | Buy |
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Nuvectis Pharma Grows Its Cash Pile While Chasing Cancer Trials - Finimize
Will Rising Costs Hurt Lancor Holdings Limited’s Margins This YearCurrency Fluctuation Impact & Free High Frequency Trading Ideas - earlytimes.in
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Nuvectis Pharma Doubles Down On R&D Despite Rising Losses - Finimize
Nuvectis Pharma Q3 net loss widens on milestone expenses - MarketScreener
Nuvectis Pharma (NASDAQ: NVCT) posts third quarter results: $7.5M net loss; runway to 3Q-2027 - Stock Titan
Nuvectis Pharma, Inc. SEC 10-Q Report - TradingView
Nuvectis Pharma reveals Q3 2025 financial performance and strategic business updates - Traders Union
Nuvectis Pharma (NASDAQ: NVCT) initiates NXP900 Phase 1b; cash at $35.4M in Q3 results - Stock Titan
What makes Nuvectis Pharma Inc. stock attractive to growth fundsJuly 2025 Setups & Detailed Earnings Play Alerts - newser.com
Does Nuvectis Pharma Inc. qualify in momentum factor screeningMarket Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Nuvectis Pharma Inc a good long term investmentStock Split Announcements & High Yield Market Growth - earlytimes.in
Why Nuvectis Pharma Inc. stock remains undervaluedEarnings Summary Report & Fast Moving Trade Plans - newser.com
Nuvectis Pharma Inc. stock trendline breakdownJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
How strong is Nuvectis Pharma Inc. stock revenue growthJuly 2025 Short Interest & Weekly Return Optimization Alerts - newser.com
How Nuvectis Pharma Inc. stock performs in rate cut cyclesJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.July 2025 Spike Watch & Capital Protection Trading Alerts - newser.com
Predicting Nuvectis Pharma Inc. trend using moving averagesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
What data driven models say about Nuvectis Pharma Inc.’s futureBull Run & Safe Capital Growth Stock Tips - newser.com
Nuvectis Pharma Shares: Poised for Significant Growth? - AD HOC NEWS
Nuvectis Pharma : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener
Insider Buying: Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Acquires 46,900 Shares of Stock - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Purchases $215,459.10 in Stock - MarketBeat
A US$22m Market Cap Boost Pleasing ToNuvectis Pharma Insiders - simplywall.st
What's Driving Renewed Interest In Nuvectis Pharma's Oncology Strategy? - RTTNews
Major Investment Alert: Insider Buys Big in Nuvectis Pharma! - TipRanks
Insider Stock Purchases: October 29, 2025 - Quiver Quantitative
Nuvectis Pharma Stock (NVCT) Opinions on NXP900 Trial Results - Quiver Quantitative
Nuvectis Pharma (NVCT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing - MarketScreener
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
Can Nuvectis Pharma Inc. stock hit analyst price targetsMarket Volume Summary & Daily Technical Forecast Reports - fcp.pa.gov.br
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target By Investing.com - Investing.com South Africa
Can Nuvectis Pharma Inc. stock reach $100 price targetJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - fcp.pa.gov.br
Will Nuvectis Pharma Inc. stock beat EPS estimatesWatch List & Consistent Growth Equity Picks - newser.com
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
| Mosseri Marlio Charles | 10% Owner |
Jun 20 '25 |
Buy |
7.99 |
5,603 |
44,768 |
2,981,806 |
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
1.22%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):